Study details
Enrolling now
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
Yale University
NCT IDNCT05786066ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
30
Study length
about 10 years
Ages
21–65
Locations
1 site in CT
About this study
Researchers are testing whether blocking AMPA receptors changes how well ketamine helps with suicidal thoughts. The trial will compare ketamine to a placebo and perampanel, a drug that blocks AMPA receptors.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Ketamine
- 2.Take Perampanel 6 MG
- 3.Take Placebo
PhasePhase 2
DrugKetamine
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
ketamine (NMDA receptor antagonist; induces dissociative anesthesia and analgesia), perampanel
Drug routes
oral (Oral Tablet)
Body systems
Psychiatry / Mental Health